X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1724) 1724
Publication (129) 129
Newsletter (23) 23
Book Review (11) 11
Magazine Article (6) 6
Book Chapter (5) 5
Conference Proceeding (4) 4
Trade Publication Article (4) 4
Book / eBook (3) 3
Data Set (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1252) 1252
cyclohexanes - therapeutic use (896) 896
male (708) 708
female (594) 594
animals (560) 560
index medicus (518) 518
middle aged (401) 401
adult (394) 394
cyclohexanes (318) 318
triazoles - therapeutic use (315) 315
cyclohexanes - pharmacology (285) 285
hiv infections - drug therapy (284) 284
pharmacology & pharmacy (260) 260
aged (257) 257
mice (257) 257
cyclohexane (247) 247
hypoglycemic agents - therapeutic use (211) 211
sesquiterpenes - therapeutic use (203) 203
phenylalanine - analogs & derivatives (196) 196
rats (193) 193
cyclohexanes - adverse effects (187) 187
cyclohexanes - administration & dosage (172) 172
phenylalanine - therapeutic use (171) 171
maraviroc (167) 167
treatment outcome (158) 158
infectious diseases (147) 147
ccr5 receptor antagonists (145) 145
anti-hiv agents - therapeutic use (138) 138
oncology (136) 136
hiv fusion inhibitors - therapeutic use (135) 135
drug therapy, combination (134) 134
hiv-1 - drug effects (130) 130
nateglinide (130) 130
diabetes mellitus, type 2 - drug therapy (129) 129
hiv infections - virology (127) 127
time factors (117) 117
triazoles - pharmacology (115) 115
analysis (113) 113
hiv (113) 113
clinical trials as topic (111) 111
immunology (111) 111
adolescent (110) 110
antineoplastic agents - therapeutic use (97) 97
double-blind method (95) 95
cancer (94) 94
microbiology (93) 93
angiogenesis inhibitors - therapeutic use (88) 88
endocrinology & metabolism (87) 87
research (87) 87
therapy (85) 85
dose-response relationship, drug (84) 84
angiogenesis (83) 83
sesquiterpenes - pharmacology (82) 82
antibiotics, antineoplastic - therapeutic use (80) 80
chlorhexidine (80) 80
dentistry (80) 80
tumor-growth (80) 80
antiviral agents (79) 79
viral load (79) 79
health aspects (78) 78
triazoles - adverse effects (77) 77
virology (77) 77
fumagillin (76) 76
tnp-470 (76) 76
disease models, animal (75) 75
agm-1470 (74) 74
sesquiterpenes (74) 74
o-fumagillol (72) 72
administration, oral (71) 71
article (71) 71
child (71) 71
drug therapy (71) 71
antiretroviral therapy (70) 70
care and treatment (70) 70
cyclohexanes - chemistry (70) 70
cyclohexanes - pharmacokinetics (69) 69
neovascularization, pathologic - drug therapy (68) 68
cd4 lymphocyte count (67) 67
dentistry, oral surgery & medicine (67) 67
clinical trials (65) 65
expression (64) 64
nitrosourea compounds - therapeutic use (64) 64
research article (64) 64
diabetes mellitus - drug therapy (62) 62
receptors, ccr5 - metabolism (62) 62
chlorhexidine - therapeutic use (61) 61
in-vitro (61) 61
blood glucose - metabolism (60) 60
ccr5 (60) 60
triazoles - administration & dosage (60) 60
aids (59) 59
efficacy (59) 59
hiv-1 - physiology (59) 59
neoplasm transplantation (59) 59
young adult (59) 59
medicine (58) 58
anti-bacterial agents - therapeutic use (56) 56
infection (56) 56
fatty acids, unsaturated - therapeutic use (55) 55
mice, nude (55) 55
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1480) 1480
German (97) 97
Japanese (52) 52
French (51) 51
Spanish (27) 27
Italian (22) 22
Chinese (9) 9
Portuguese (5) 5
Russian (5) 5
Czech (3) 3
Polish (3) 3
Dutch (2) 2
Danish (1) 1
Finnish (1) 1
Hungarian (1) 1
Romanian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Heart Journal, ISSN 0195-668X, 09/2015, Volume 36, Issue 34, pp. 2288 - 2296
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 16, pp. 1477 - 1490
In this large clinical trial, the angiotensin-receptor blocker valsartan reduced the risk of diabetes in patients with impaired glucose tolerance. However, the... 
FASTING GLUCOSE | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | METABOLIC SYNDROME | LIFE-STYLE INTERVENTIONS | PREVENTION | COMPONENTS | IMPAIRED GLUCOSE-TOLERANCE | MELLITUS | CONVERTING-ENZYME-INHIBITORS | Angiotensin II Type 1 Receptor Blockers - adverse effects | Follow-Up Studies | Phenylalanine - analogs & derivatives | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Body Weight - drug effects | Male | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Cyclohexanes - therapeutic use | Glucose Intolerance - drug therapy | Exercise | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Phenylalanine - therapeutic use | Drug Therapy, Combination | Hypoglycemic Agents - therapeutic use | Blood Glucose - analysis | Double-Blind Method | Risk Factors | Valine - analogs & derivatives | Diabetes Mellitus, Type 2 - prevention & control | Proportional Hazards Models | Blood Glucose - drug effects | Glucose Intolerance - diet therapy | Tetrazoles - therapeutic use | Valine - therapeutic use | Tetrazoles - adverse effects | Valine - adverse effects | Glucose Intolerance - therapy | Evaluation | Care and treatment | Glucose intolerance | Diabetes | Cardiovascular diseases | Drug therapy | Cardiovascular disease | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 16, pp. 1463 - 1476
Among patients with impaired glucose tolerance, the short-acting insulin secretagogue nateglinide did not reduce the incidence of diabetes over the course of 5... 
TRIAL | MEDICINE, GENERAL & INTERNAL | LIFE-STYLE | DIET | INSULIN-SECRETION | DISEASE | PREVENTION | IMPAIRED GLUCOSE-TOLERANCE | ACARBOSE | MELLITUS | NIDDM | Follow-Up Studies | Phenylalanine - adverse effects | Phenylalanine - analogs & derivatives | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Body Weight - drug effects | Male | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Cyclohexanes - therapeutic use | Glucose Intolerance - drug therapy | Exercise | Treatment Failure | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Cyclohexanes - adverse effects | Phenylalanine - therapeutic use | Drug Therapy, Combination | Hypoglycemic Agents - therapeutic use | Blood Glucose - analysis | Double-Blind Method | Risk Factors | Valine - analogs & derivatives | Diabetes Mellitus, Type 2 - prevention & control | Kaplan-Meier Estimate | Proportional Hazards Models | Blood Glucose - drug effects | Glucose Intolerance - diet therapy | Tetrazoles - therapeutic use | Valine - therapeutic use | Hypoglycemic Agents - adverse effects | Glucose Intolerance - therapy | Evaluation | Care and treatment | Glucose intolerance | Diabetes | Cardiovascular diseases | Drug therapy | Nateglinide | Studies | Cardiovascular disease | Clinical Medicine | Allmänmedicin | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | General Practice
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1442 - 1455
In key subgroups of the HIV-infected patients in the MOTIVATE 1 and MOTIVATE 2 studies, a consistent treatment benefit of maraviroc over placebo was seen at 48... 
CCR5 ANTAGONIST | MEDICINE, GENERAL & INTERNAL | EFFICACY | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | ACTIVE ANTIRETROVIRAL THERAPY | DRUG-RESISTANT HIV-1 | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | HEPATITIS-C | PROGNOSTIC VALUE | Triazoles - adverse effects | Humans | Middle Aged | Receptors, CCR5 - genetics | Male | RNA, Viral - blood | Hepatitis B - blood | Viral Load | Hepatitis B - complications | Cyclohexanes - therapeutic use | HIV Infections - immunology | Ethnic Groups | HIV Envelope Protein gp41 - therapeutic use | HIV-1 - chemistry | Hepatitis C - blood | Adult | Female | Hepatitis C - complications | Cyclohexanes - adverse effects | Drug Therapy, Combination | Odds Ratio | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Anti-Retroviral Agents - therapeutic use | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Genotype | Treatment Outcome | CD4 Lymphocyte Count | HIV Fusion Inhibitors - adverse effects | HIV-1 - genetics | HIV Fusion Inhibitors - therapeutic use | HIV Infections - drug therapy | Transaminases - blood | Aged | Peptide Fragments - therapeutic use | Antiviral agents | Care and treatment | Maraviroc | Comparative analysis | Health aspects | HIV infection | Drug therapy | Drug resistance | Human immunodeficiency virus--HIV | Chemokines | Index Medicus | Abridged Index Medicus
Journal Article